RecruitingNCT05995418

Study on the Health Economic Burden of Alzheimer's Disease in China

The Alzheimer's Disease Burden in China (ABC) Study: a Nationwide Multicentre Cross-sectional and Prospective Cohort Study


Sponsor

Xuanwu Hospital, Beijing

Enrollment

9,510 participants

Start Date

Jul 1, 2023

Study Type

OBSERVATIONAL

Conditions

Summary

Alzheimer's disease (AD) presents a significant socio-economic challenge globally, with China experiencing a notable rise in its prevalence. This study addresses critical gaps in understanding AD's economic burden and quality of life (QoL) impacts on patients and caregivers in Mainland China.


Eligibility

Min Age: 40 YearsMax Age: 100 Years

Inclusion Criteria2

  • Diagnosed according to the National Institute on Aging-Alzheimer's 1.Association (NIA-AA) criteria for aMCI and AD.
  • Clinical Dementia Rating (CDR) score greater than or equal to 0.5 3.Have good visual, auditory, and language functions, or can complete neuropsychological assessments after correction.

Exclusion Criteria5

  • History of stroke with neurological focal signs and imaging findings consistent with cerebral small vessel disease (Modified Fazekas score ≥2).
  • Presence of mental or neurological developmental delay.
  • Presence of other known conditions that may cause cognitive impairment.
  • Diagnosis of a disease that prevents completion of cognitive assessments.
  • Refusal to sign informed consent at baseline.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERThere was no intervention as this was an observational study.

There was no intervention as this was an observational study.


Locations(1)

Xuanwu Hospital, Capital Medical University

Beijing, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05995418


Related Trials